CABA CABALETTA BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, CABALETTA BIO INC reported revenue of n/a, net income of −$51.0M and diluted EPS of −$0.34; for the fiscal year ended December 2025 revenue was n/a.
CABA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$172M, net income −$168M (margin n/a), EPS −$2.10
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$125M, net income −$116M (margin n/a), EPS −$2.34
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$74.7M, net income −$67.7M (margin n/a), EPS −$1.65
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$54.1M, net income −$53.0M (margin n/a), EPS −$1.81
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$46.3M, net income −$46.3M (margin n/a), EPS −$1.80
CABA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$51.0M, EPS −$0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$43.5M, EPS −$0.39
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$41.9M, EPS −$0.22
- Quarter ended Sep 30, 2025: revenue n/a, net income −$44.9M, EPS −$0.44
- Quarter ended Jun 30, 2025: revenue n/a, net income −$45.1M, EPS −$0.73
- Quarter ended Mar 31, 2025: revenue n/a, net income −$35.9M, EPS −$0.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$32.6M, EPS −$0.65
- Quarter ended Sep 30, 2024: revenue n/a, net income −$30.6M, EPS −$0.62
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.6M, EPS −$0.56
- Quarter ended Mar 31, 2024: revenue n/a, net income −$25.0M, EPS −$0.51
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$20.9M, EPS −$0.46
- Quarter ended Sep 30, 2023: revenue n/a, net income −$16.4M, EPS −$0.37
- Quarter ended Jun 30, 2023: revenue n/a, net income −$14.5M, EPS −$0.37
- Quarter ended Mar 31, 2023: revenue n/a, net income −$15.9M, EPS −$0.45
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$15.7M, EPS −$0.52
- Quarter ended Sep 30, 2022: revenue n/a, net income −$11.4M, EPS −$0.39
- Quarter ended Jun 30, 2022: revenue n/a, net income −$12.9M, EPS −$0.45
- Quarter ended Mar 31, 2022: revenue n/a, net income −$12.9M, EPS −$0.45
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$13.9M, EPS −$0.49
- Quarter ended Sep 30, 2021: revenue n/a, net income −$11.6M, EPS −$0.45
CABA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$131M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$88.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$53.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$46.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$34.1M, share buybacks n/a
CABA balance sheet
- Jun 30, 2026: cash $225M, total assets $257M, total liabilities $46.1M, shareholders' equity $211M
- Mar 31, 2026: cash $117M, total assets $148M, total liabilities $44.8M, shareholders' equity $103M
- Dec 31, 2025: cash $83.0M, total assets $165M, total liabilities $53.0M, shareholders' equity $112M
- Sep 30, 2025: cash $60.2M, total assets $190M, total liabilities $50.3M, shareholders' equity $139M
- Jun 30, 2025: cash $146M, total assets $225M, total liabilities $46.0M, shareholders' equity $178M
- Mar 31, 2025: cash $132M, total assets $165M, total liabilities $43.6M, shareholders' equity $122M
- Dec 31, 2024: cash $164M, total assets $185M, total liabilities $32.7M, shareholders' equity $152M
- Sep 30, 2024: cash $171M, total assets $204M, total liabilities $30.2M, shareholders' equity $174M
Is CABA profitable?
No. CABALETTA BIO INC lost $181M over the last four quarters.
What is CABA's EPS?
Diluted earnings per share over the last four quarters were −$1.39; −$0.34 in the latest quarter.